Commentary on Novitas LCD

IF 1 4区医学 Q4 ONCOLOGY

Bladder Cancer Pub Date : 2023-09-28 DOI:10.3233/blc-230057

Yair Lotan, Daniel A. Barocas, Sam S. Chang, Siamak Daneshmand, Badrinath Konety, Joshua J. Meeks, Sima Porten, Jay D. Raman, Charles J. Rosser, Kristen R. Scarpato, Wade J. Sexton, John P. Sfakianos, Neal D. Shore, Robert S. Svatek

引用次数: 0

Abstract

The role of biomarkers (aka, markers) in detecting and managing cancer is an evolving field. It is crucial to develop biomarkers robustly that mirror drug development in the pharmaceutical

查看原文本刊更多论文

Novitas LCD评论

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bladder Cancer Medicine-Urology

CiteScore

1.60

自引率

0.00%

发文量

期刊介绍： Bladder Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the bladder and upper urinary tract. The journal publishes research reports, reviews, short communications, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that expedites our fundamental understanding and improves treatment of tumors of the bladder and upper urinary tract.